Little-known provisions in the Big Beautiful Bill lobbied by industry will cost Medicare billions in missed savings.

Merck faces intense pressure from new global tariffs and a looming Keytruda patent expiration, but is fighting back with a $3 ...

Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove ...

Shipments to China are now paused through the end of 2025, dragging global sales of the HPV vaccine down 55% last quarter.

Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug ...

Of the companies that reported their results last week, 18 beat analysts’ earnings forecasts, while 3 missed. On the revenue ...

Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...

Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support ...

Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey drugmaker told Fierce Pharma. | Merck will reduce its workforce by ...

Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to ...

Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe ...